-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 10, the recombinant new coronavirus vaccine (CHO cell) jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Zhifei Biotechnology was approved for emergency use in China, becoming the fourth domestic new coronavirus vaccine approved for emergency use.
It is reported that the vaccine has completed Phase I and Phase II clinical trials in October last year.
In November last year, the vaccine successively launched phase III clinical trials in China, Uzbekistan, Pakistan, Ecuador, and Indonesia, with 29,000 patients planned to be vaccinated.
It is reported that the vaccine production uses engineered cells (CHO) to produce recombinant proteins, and does not require high-grade biosafety laboratory production workshops.